Source: EV Battery Tech.
  • EV Battery Tech (ACDC) has closed its oversubscribed non-brokered private placement for total gross proceeds of $900,000
  • The company issued a total of 4,500,000 units at a price of $0.20 per unit
  • Net proceeds will be used for the development of its crypto mining facility, marketing and general working capital
  • Extreme Vehicle Battery Technologies provides scalable, smart solutions for the electric vehicle and energy storage markets
  • EV Battery Tech (ACDC) opened trading at C$0.10 per share

EV Battery Tech (ACDC) has closed its previously announced oversubscribed non-brokered private placement for total gross proceeds of $900,000.

“This private placement shows the considerable strength of the company and the faith investors have in its long-term business plan,” stated Bryson Goodwin, President and CEO of EV Battery Tech.

The company issued a total of 4,500,000 units at a price of $0.20 per unit. Each unit consists of one common share and one share purchase warrant. Each warrant is exercisable into one additional common share at a price of $0.25 for a period of three years.

Warrants are subject to an acceleration clause.

All securities issued are subject to a four-month hold period.

Net proceeds will be used for the development of its crypto mining facility, marketing and general working capital.

Extreme Vehicle Battery Technologies provides scalable, smart solutions for the electric vehicle and energy storage markets.

EV Battery Tech (ACDC) opened trading at C$0.10 per share.

More From The Market Online

Westinghouse Electric files for US IPO

Westinghouse Electric Company, jointly owned by Cameco and Brookfield Renewable Partners, confidentially filed for a US IPO.

Buzz on the Bullboards: Contracts, cashflows, and delistings

Uncertainty around Iran has weighed on sentiment, reminding investors that even strong stories can be overshadowed by geopolitical risk.

EU authorizes new COVID vaccine from Pfizer and BioNTech

The EU grants marketing authorization to Pfizer and BioNTech's COVID-19 vaccine targeting the new XFG variant.